| Literature DB >> 35208860 |
Abdul-Rehman Phull1, Madiha Ahmed2, Hye-Jin Park1.
Abstract
Cordyceps militaris (C. militaris) is a medicinal mushroom possessing a variety of biofunctionalities. It has several biologically important components such as polysaccharides and others. The diverse pharmacological potential of C. militaris has generated interest in reviewing the current scientific literature, with a particular focus on prevention and associated molecular mechanisms in inflammatory diseases. Due to rising global demand, research on C. militaris has continued to increase in recent years. C. militaris has shown the potential for inhibiting inflammation-related events, both in in vivo and in vitro experiments. Inflammation is a multifaceted biological process that contributes to the development and severity of diseases, including cancer, colitis, and allergies. These functions make C. militaris a suitable functional food for inhibiting inflammatory responses such as the regulation of proinflammatory cytokines. Therefore, on the basis of existing information, the current study provides insights towards the understanding of anti-inflammatory activity-related mechanisms. This article presents a foundation for clinical use, and analyzes the roadmap for future studies concerning the medical use of C. militaris and its constituents in the next generation of anti-inflammatory drugs.Entities:
Keywords: COX-2; Cordyceps militaris; inflammation; matrix metalloproteinases; pharmacokinetics; polysaccharides
Year: 2022 PMID: 35208860 PMCID: PMC8875674 DOI: 10.3390/microorganisms10020405
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1Natural (A) and cultivated (B) C. militaris.
Figure 2Chemical structure of six nucleosides.
Figure 3Chemical structure of cordycepin.
Figure 4Pharmacological potential of Cordyceps militaris and its constituents.
Figure 5Triggering, pathological consequences, and physiological significance of inflammation.
Biofunctional components, concentration, experimental/disease model and anti-inflammatory actions of Cordyceps militaris.
| Bioactive Component | Dose/Disease Model | Study Type/Experimental Model | Results/Mechanism | References |
|---|---|---|---|---|
| Cordycepin | 2.5–10 mg per kg of rat/Parkinson’s disease | In vivo/ | Reduced neuro-inflammation, dynamin-related protein 1 (Drp1), IL-1β, IL-18 and tyrosine hydroxylase. Amplified NLRP3 inflammasome activation, ATP production, AMP-activated protein kinase and mitochondrial functions | [ |
| Cordycepin | 0.0005–0.008 nM/L | In vitro/ | Improved mitochondrial functioning by increased ATP content, maintaining membrane potential, inhibiting fission protein 1(Fis1) and mitochondrial ROS levels. | [ |
| Cordycepin | 0–40 µg per mL/ | In vitro/ | Restoration of cell proliferation and osteogenic differentiation by regulating Runx2 and Osx mRNA expressions, and NF-κB signaling via inhibition of IκBα phosphorylation. | [ |
| Cordycepin | 0–40 µg per mL/LPS-stimulated RAW264.7 cells | In vitro/ | Reduced proinflammatory chemicals such as IL-1β, IL-6, TNF-α, iNOS, COX-2 and NO synthesis | [ |
| 20, 50, 100 mg per kg of rat/Focal cerebral ischemia | In vivo/ | Neuroprotection, inhibited MCP-1-induced microglial migration, oedema and the infiltration of ED-1-and MPO-positive inflammatory cells. | [ | |
| 0–40 µg per mL/LPS-induced RAW264.7 macrophages | In vitro/ | Amelioration of LPS-stimulated phosphorylation levels of MAPKs (p38, JNK1/2, and ERK1/2), NO synthase expression, IL-6 and TNF-α. | [ | |
| Cordycepin | 10, 20, 400 mg per kg of rat/ | In vivo/ | Inhibited OVA-specific immunoglobulin (Ig) E, mucus hypersecretion, eotaxin, IL-4, -5, -13 and ICAM-1, NF-kB activation and p38-MAPK signaling cascades, recruitment of inflammatory cells in an experimental model. | [ |
| Militarin Derivatives | 0–100 µM/ | In vitro/ | Inhibited NO production and PGE2 by downregulating p38/AP-1, IKKe/IRF-3, and Syk/NF-kB pathways | [ |
| Militarin Derivatives | 5–20 mg per kg in DSS-induced colitis, | In vivo/ | Anti-inflammatory effects by reducing gastric damage (gastritis), inhibited colon size and up-regulated phospho-p38 (colitis), and inhibited ear oedema. | [ |
| Cordycepin | 0, 1, 10 and 100 µg per mL/ | In vitro/ | Inhibition of inflammation by reducing expression of M1 chemokines (CX3CR1, RANTES) and cytokines (IL-1β, TNF-α). | [ |
| Extract of | 5–20 mg per kg of mice/ | In vivo/ | Inhibited TNF-𝛼, iNOS, MMP-3, MMP-9 mRNA Expressions in colonic tissue of a colitis model. | [ |
| Extract of | 10 and 100 µg per mL/ | In vitro/ | Suppressed TNF-𝛼 and iNOS in a cell model | [ |
| Extract (Mulberry leaves fermented with | High fat diet-induce -obese mice | In vivo/ | Inhibited mast cell infiltration, COX-2, iNOS, IL-6, -1β, TNF-α, NF-κB. Anti-inflammatory response via the PI3K/AKT/mTOR signaling pathway. | [ |
| Cordycepin | 0, 10, 50 or 100 µM/ | In vitro/ | Increased type-II collagen, aggrecan synthesis. Inhibited PGE2, NO, and matrix damaging enzymes (MMP-3, -13; ADAMTS-4, and -5). | [ |
| 0.1, 1, 10 and 100 µg per mL/ LPS-stimulated BV2 microglia cells | In vitro/ | Significantly reduction in LPS induced nitric oxide. | [ | |
| 0.603–1.809 g per kg per day/ | In vivo/ | Suppressed proinflammatory cytokines, such as TNF-α, IL-6, and NF-κB. | [ | |
| Cordycepin, | 0–30 µg of Cordycepin per mL/ or | In vitro/ | Anti-inflammatory effect by inhibiting NO synthesis, NF-κB activation, iNOS, COX-2 expressions and phosphorylation of p38 and Akt. | [ |
| Ergosterol palmitate; palmitic acid; ergosterol; ergosterol peroxide; 3,4- | LPS/IFN-α stimulated murine peritoneal macrophage cells | In vitro/ | Suppressed synthesis of cytokines including IL-12 and TNF-α and NO production | [ |
| Soya-cerebroside, | 0, 1, 5, and 10 µM/ | In vitro/ | Reduced monocytes migration and MCP-1 expressions. Downregulated SP1 expression by activating miR-432 and inducing phosphorylation of AKT and AMPK. | [ |
| Soya-cerebroside, | 3 and 10 mg per kg per day/ | In vivo/ | Inhibited edema and cartilage damage. Induction in CD68 and MCP-1 (a marker for monocyte/macrophages) positive cells, | [ |
| Soya-cerebroside | 0, 1, 5, and 10 µM/ | In vitro/ | Decreased monocyte migration, activated AKT and AMPK signaling pathways, MCP-1 and microRNA (miR)-432 expression in OASFs. | [ |
| 1, 10, 100 and 1000 µg per mL/ | In vitro/ | Inhibited nitrite production, iNOS, and TNF-α. | [ | |
| 500 mg per kg of animal per day/ | In vivo/ | Alleviated the severity of the disease in a colitis mouse model by decreasing mRNA expression of TNF- α and iNOS. | [ | |
| GRC, | 250, 500 µg per mL/ | In vitro/ | Reduced NO production, iNOS, COX-2, and TNF-α mRNA expression, and that of MAPKs (ERK, JNK, and P38), NF-κB. | [ |
| GRC, | 25 mg per kg of animal/ | In vivo/ | Decreased inflammatory response such as ear swelling in an experimental model | [ |
| Cordycepin | 12.5, 25, 50, 100 µg per mL/ | In vitro/ | Anti-inflammatory effect by down regulating NLRP3 inflammasome activation and NF-κB via AMPK. | [ |
| Cordycepin | 100 mg per kg of animal/ | In vivo/ | Augmented neutrophil infiltration and reduced edema, acinar cell vacuolization, serum amylase, lipase levels. Inhibited TNF-α, IL-1β, IL-6 by suppressing the activation of NLRP3 inflammasome and NF-κB. | [ |
| 1 and 2 g per kg of animal/ | In vivo/ | Amplification of total protein, serum albumin, MDA, SOD, and glutathione peroxidase. Attenuated IL-1, TNF-α, 6-keto-PGF1α, NF-κB p65. Reduced serum levels of VCAM-1, ICAM-1, and MCP-1 and urine protein serum creatinine, triglyceride, blood urea nitrogen and total cholesterol. | [ | |
| Extract of fruiting bodies | 500 µg per mL/ | In vitro/ | Reduced Synthesis of IL-6, NO, and TNF-α. | [ |
| Cordycepin | 50, 100, and 200 g per kg / | In vivo/ | Inhibition of Nrf2 and HO-1 expressions, MDA content, IL-1β, TNF-α and NF-κB activation. | [ |
| 50 and 100 µg per mL/ | Ex vivo/ | Suppressed COX-2, iNOS, IL-1β, IL-6, TNF-α, IFN-γ) and NO synthesis | [ | |
| 25 and 50 µg per mL/ | In vitro/ | Reduced expression of proinflammatory cytokines (TNF-α, IL-1β, IKKa, iNOS, IL-6, NF-kß) and NO production. | [ | |
| Mulberry leaves fermented with | 100, 200 and 400 μg per mL/ | In vitro/ | Anti-inflammatory activity by iNOS-mediated COX-2, expression of inflammatory cytokines (IL-1β, IL-6 and TNF-α), and MAPK signaling pathway | [ |
| Cordycepin | 10, 50 and 100 μM/ | Ex vivo/ | Suppressed IL-1β, PGE2, MMP-13, IL-6, iNOS, COX-2 and NO synthesis. | [ |
| Cordycepin | PBMCs (Kawasaki disease patients), LPS-induced Macrophages | In vitro and Ex-Vivo/ PBMCs, macrophages | Inhibition of LPS-stimulated TNFα production in mouse macrophages and in PBMCs | [ |
| Cordycepin | 1, 5, 10 and 20 mg per kg/ | In vivo/ | Increased arginase 1 and IL-10. Inhibition of IL-1β, iNOS, MPO and MMP-9, and NADPH oxidase expression. | [ |
| 4 g per kg/ | In vivo/ | Inhibited asthmatic airway inflammation and blocked bronchoconstriction mediators-leukotrienes | [ | |
| 50, 100 and 200 µg per mL/ | In vitro/ | Decreased proinflammatory cytokines, TNF-α and IL-6 in a concentration-dependent manner. In addition, showed nitric oxide inhibitory activity. | [ | |
| Cordycepin | 50 and 100 μM/ | In vitro/ | Attenuated the increased expression of inflammatory genes (TNF-α, IL-1β, Cxcl10, Ccl2 and Ccl5) | [ |
| Cordycepin | 100 and 200 mg per kg/ | In vivo/ | Suppressed inflammatory genes (IL-1β, Cxcl2, Cxcl10, Ccl2, and Ccl5), activation of NF-κB signaling, and inflammatory cell infiltration. Anti-inflammatory effects through AMPK pathways | [ |
| Spent mushroom ( | 0.5, 1 and 1.5 g per kg/ | In vitro/ | Improved health conditions. Inhibition of IL-1β and TNF-α. | [ |
| Fermented | 0–300 µg per mL/ | In vitro/ | IL-4 and TNF-α inhibition | [ |
| Cordycepin | 2 g per liter in drinking water/ | In vivo/ | Inhibition of COX-2 and iNOS | [ |
| 3, 1.5, and 0.5 g powder per individual/ | In vivo/ | Suppressed inflammatory cytokines including EGF, eotaxin, fractalkine, IP-10, IL-1α, -6, -8, IFN-α2, -γ, MIP-1α, -1β, GRO, G-CSF, GM-CSF, MCP-1, sCD40L, TGF-α, VEGF | [ |
Abbreviations: 1-fluoro-2,4-dinitrofluorobenzene: DNFB; Adipose-derived mesenchymal stem cells: ADMSCs; Cordyceps militaris grown on germinated Rhynchosia nulubilis: GRC; Cyclooxygenase 2: COX-2; Dextran sodium sulfate-induced: DSS; Epidermal growth factor: EGF; Fibroblast growth factor-2: FGF-2; Granulocyte-colony stimulating factor: G-CSF; Granulocyte-macrophage colony-stimulating factor: GM-CSF; GRC: fermented with Pediococcus pentosaceus ON89A isolated from onion hexane extract: GRC-ON89A; Growth regulated oncogene: GRO; Interferon-α2 (IFN-α2), IFN-γ; Heme oxygenase-1: HO-1; IFN-γ inducible protein 10: IP-10; Inducible NO synthase: iNOS; Intercellular adhesion molecule 1: ICAM-1; Interleukin-1α: (IL)-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17; Lipopolysaccharide: LPS; Macrophage inflammatory protein-1α: (MIP)-1α, MIP-1β; Macrophage-derived chemokine: MDC; Malondialdehvde: MDA; Monocyte chemoattractant protein-1: (MCP)-1, MCP-3; Monocyte chemoattractant protein-1: MCP-1; Nuclear factor erythroid 2–related factor 2: Nrf2; Nuclear factor-κB: NF-κB; Mitogen -activated protein kinases: MAPKs; Ovalbumin: OVA; Peripheral Blood Mononuclear Cells: PBMCs; Transforming growth factor-α: TGF-α; Tumor necrosis factor alpha: TNF-α; Tumor necrosis factor-α: (TNF)-α, TNF-β; Vascular endothelial growth factor: VEGF; Vascular adhesion molecule 1: VCAM-1.
Figure 6C. militaris and its constituents associated anti-inflammatory molecular mechanisms. Arachidonic acid: A.A; Cyclooxygenase 2: COX-2; Heme oxygenase-1: HO-1; Interleukin-1β: (IL)-1β, -4, -5, -6, -10, -12, -13, -18; Intracellular adhesion molecule: ICAM; Inducible nitric oxide synthase: iNOS; Leukotrienes LT; Lipoxygenases: LOX; Monocyte chemotactic protein-1: MCP-1; Matrix metalloproteinases: MMPs; Nuclear factor-κB: NF-κB; phospholipase A2: PLA-2; Glutathione peroxidase: GPx; Prostaglandin: PG; Superoxide dismutase: SOD; Transforming growth factor-α: TGF-α; Tumor necrosis factor alpha: TNF-α; Vascular endothelial growth factor: VEGF; Vascular cell adhesion molecule: VCAM. Upward double arrow shows the improved/increased content or functionality. Single black arrow indicates signaling cascades, while the red symbol specifies the inhibition of inflammation associated signals and biomolecules.